Latest Insider Transactions at Generation Bio Co. (GBIO)
This section provides a real-time view of insider transactions for Generation Bio Co. (GBIO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Generation Bio Co. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Generation Bio Co.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
10,500
-2.55%
|
$357,000
$34.92 P/Share
|
|
Mar 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,500
+4.79%
|
$0
$0.6 P/Share
|
|
Mar 05
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
11,267
-0.48%
|
$360,544
$32.79 P/Share
|
|
Mar 05
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,267
+3.23%
|
$45,068
$4.59 P/Share
|
|
Mar 03
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
3,000
-100.0%
|
$123,000
$41.38 P/Share
|
|
Mar 03
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+50.0%
|
$12,000
$4.59 P/Share
|
|
Mar 01
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-48.95%
|
$95,000
$38.61 P/Share
|
|
Mar 01
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$10,000
$4.59 P/Share
|
|
Mar 01
2021
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
10,000
-0.28%
|
$370,000
$37.3 P/Share
|
|
Feb 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
10,400
-1.69%
|
$353,600
$34.64 P/Share
|
|
Feb 10
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,400
+4.75%
|
$0
$0.6 P/Share
|
|
Feb 08
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
11,267
-1.68%
|
$371,811
$33.55 P/Share
|
|
Feb 08
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,267
+3.23%
|
$45,068
$4.59 P/Share
|
|
Feb 02
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$82,500
$33.05 P/Share
|
|
Feb 02
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$10,000
$4.59 P/Share
|
|
Jan 15
2021
|
Mark D. Angelino CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
7,500
-0.53%
|
$247,500
$33.64 P/Share
|
|
Jan 15
2021
|
Mark D. Angelino CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+2.08%
|
$30,000
$4.59 P/Share
|
|
Jan 14
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
5,630
-1.39%
|
$180,160
$32.56 P/Share
|
|
Jan 14
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,630
+2.69%
|
$0
$0.6 P/Share
|
|
Jan 14
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
2,500
-100.0%
|
$82,500
$33.09 P/Share
|
|
Jan 14
2021
|
Tracy Zimmermann CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+50.0%
|
$10,000
$4.59 P/Share
|
|
Jan 13
2021
|
Geoff Mcdonough PRESIDENT AND CEO |
BUY
Bona fide gift
|
Indirect |
275,000
+50.0%
|
-
|
|
Jan 13
2021
|
Geoff Mcdonough PRESIDENT AND CEO |
SELL
Bona fide gift
|
Direct |
275,000
-18.59%
|
-
|
|
Jan 11
2021
|
Charles A Rowland Jr |
BUY
Open market or private purchase
|
Direct |
20,408
+16.8%
|
$489,792
$24.5 P/Share
|
|
Jan 11
2021
|
Donald William Nicholson |
BUY
Open market or private purchase
|
Direct |
4,081
+3.81%
|
$97,944
$24.5 P/Share
|
|
Jan 11
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
14,820
-2.36%
|
$400,140
$27.99 P/Share
|
|
Jan 11
2021
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
14,820
+6.51%
|
$0
$0.6 P/Share
|
|
Jan 11
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
11,267
-1.12%
|
$315,476
$28.01 P/Share
|
|
Jan 11
2021
|
Douglas Kerr CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
11,267
+3.23%
|
$45,068
$4.59 P/Share
|
|
Dec 15
2020
|
Mark D. Angelino CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
5,301
-0.76%
|
$185,535
$35.2 P/Share
|
|
Dec 15
2020
|
Mark D. Angelino CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,301
+1.49%
|
$21,204
$4.59 P/Share
|
|
Dec 15
2020
|
Atlas Venture Fund X, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,151,882
-9.12%
|
-
|
|
Dec 10
2020
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
10,540
-1.71%
|
$389,980
$37.92 P/Share
|
|
Dec 10
2020
|
Matthew Stanton CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,540
+4.81%
|
$0
$0.6 P/Share
|
|
Jun 16
2020
|
Casdin Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
650,000
+28.75%
|
$12,350,000
$19.0 P/Share
|
|
Jun 16
2020
|
Casdin Capital, LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
961,215
+50.0%
|
-
|
|
Jun 16
2020
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
800,000
+22.14%
|
$15,200,000
$19.0 P/Share
|
|
Jun 16
2020
|
Invus Public Equities, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,014,191
+50.0%
|
-
|
|
Jun 16
2020
|
Zone Healthcare Holdings, LLC |
BUY
Open market or private purchase
|
Direct |
400,000
+17.25%
|
$7,600,000
$19.0 P/Share
|
|
Jun 16
2020
|
Zone Healthcare Holdings, LLC |
BUY
Conversion of derivative security
|
Direct |
1,518,819
+50.0%
|
-
|
|
Jun 16
2020
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
225,000
+15.94%
|
$4,275,000
$19.0 P/Share
|
|
Jun 16
2020
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
961,215
+35.58%
|
-
|